Rodrigues Márcio, Alves Gilberto, Francisco Joana, Fortuna Ana, Falcão Amílcar
1 Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, Coimbra, Portugal. 2 CNC - Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. 3 CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal.
J Pharm Pharm Sci. 2014;17(3):302-15. doi: 10.18433/j3559n.
Carica papaya has been traditionally used worldwide in folk medicine to treat a wide range of ailments in humans, including the management of obesity and digestive disorders. However, scientific information about its potential to interact with conventional drugs is lacking. Thus, this work aimed to investigate the interference of a standardized C. papaya extract (GMP certificate) on the systemic exposure to amiodarone (a narrow therapeutic index drug) in rats.
In the first pharmacokinetic study, rats were simultaneously co-administered with a single-dose of C. papaya (1230 mg/kg, p.o.) and amiodarone (50 mg/kg, p.o.); in the second study, rats were pre-treated for 14 days with C. papaya (1230 mg/kg/day, p.o.) and received amiodarone (50 mg/kg, p.o.) on the 15th day. Rats of the control groups received the herbal extract vehicle. Blood samples were collected before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following amiodarone administration; in addition, at 24 h post-dose, blood and tissues (heart, liver, kidneys and lungs) were also harvested. Thereafter, the concentrations of amiodarone and its major metabolite (mono-N-desethylamiodarone) were determined in plasma and tissue samples employing a high-performance liquid chromatography-diode array detection method previously developed and validated.
In both studies was observed a delay in attaining the maximum plasma concentrations of amiodarone (tmax) in the rats treated with the extract. Nevertheless, it must be highlighted the marked increase (60-70%) of the extent of amiodarone systemic exposure (as assessed by AUC0-t and AUC0-∞) in the rats pre-treated with C. papaya comparatively with the control (vehicle) group.
The results herein found suggest an herb-drug interaction between C. papaya extract and amiodarone, which clearly increase the drug bioavailability. To reliably assess the clinical impact of these findings appropriate human studies should be conducted.
番木瓜在世界各地的民间医学中一直被用于治疗人类的多种疾病,包括肥胖症和消化系统疾病的管理。然而,关于其与传统药物相互作用潜力的科学信息却很缺乏。因此,本研究旨在调查一种标准化的番木瓜提取物(具有GMP证书)对大鼠体内胺碘酮(一种治疗指数狭窄的药物)全身暴露的影响。
在第一项药代动力学研究中,大鼠同时口服单剂量的番木瓜(1230毫克/千克)和胺碘酮(50毫克/千克);在第二项研究中,大鼠用番木瓜(1230毫克/千克/天,口服)预处理14天,并在第15天接受胺碘酮(50毫克/千克,口服)。对照组大鼠接受草药提取物赋形剂。在给药前以及胺碘酮给药后0.25、0.5、1、2、4、6、8和12小时采集血样;此外,在给药后24小时,还采集血液和组织(心脏、肝脏、肾脏和肺)样本。此后,采用先前开发并验证的高效液相色谱 - 二极管阵列检测方法测定血浆和组织样本中胺碘酮及其主要代谢物(单 - N - 去乙基胺碘酮)的浓度。
在两项研究中均观察到提取物处理的大鼠达到胺碘酮最大血浆浓度(tmax)的时间延迟。然而,必须强调的是,与对照组(赋形剂)相比,用番木瓜预处理的大鼠中胺碘酮全身暴露程度(通过AUC0 - t和AUC0 - ∞评估)显著增加(60 - 70%)。
本文的研究结果表明番木瓜提取物与胺碘酮之间存在草药 - 药物相互作用,这明显增加了药物的生物利用度。为了可靠地评估这些发现的临床影响,应进行适当的人体研究。